营养支持降低了心力衰竭患者的循环细胞因子
Aura D Herrera-Martínez1,2, Concepción Muñoz Jiménez1,2, Ana Navas Romo1,3
1Maimonides Institute for Biomedical Research of Cordoba (IMIBIC), Av. Menéndez Pidal s/n, 14004 Córdoba, Spain.
Nutrients
|June 19, 2024
概括
这项研究发现,与地中海饮食相结合的omega-3丰富的口服营养补充剂 (ONS) 降低了心力衰竭 (HF) 患者的炎症性细胞因子. 单细胞化学吸引蛋白-1 (MCP-1) 已成为HF患者死亡率的独立预测因素.
科学领域:
- 心脏病学 心脏病学
- 营养科学 营养科学
- 炎症研究 炎症研究
背景情况:
- 炎症在心力衰竭 (HF) 发病过程中起着关键作用.
- 循环中细胞因子的升高与HF患者的临床结果较差有关.
- 调节炎症是一种潜在的治疗策略,用于HF.
研究的目的:
- 为了比较仅接受地中海饮食的HF患者循环细胞因子的变化与与omega-3丰富的口服营养补充剂 (ONS) 进行地中海饮食的变化.
- 调查特定细胞因子,身体组成和HF患者的死亡率之间的关联.
主要方法:
- 随机对照试验比较地中海饮食 (控制) 与地中海饮食加上ONS (干预).
- 评估了细胞因子 (IL-6,IL-8,MCP-1,IP-10) 和炎症标志物的循环水平.
- 与体重指数,脂肪量,C反应蛋白 (CRP) 和死亡率相关的细胞因子水平.
主要成果:
- 仅地中海饮食就降低了IL-8水平.
- 添加ONS进一步降低了IL-6和IP-10水平.
- 单细胞化学吸引蛋白-1 (MCP-1) 和IL-6与超重/肥胖和脂肪量增加有关.
- MCP-1被确定为HF患者死亡的独立预测因子.
结论:
- 与地中海饮食一起使用omega-3丰富的ONS的营养支持可能会降低HF患者的特定循环细胞因子.
- 这种营养干预可能会改善心脏功能.
- 作为心力衰竭的预后标志物,MCP-1需要进一步调查.
更多相关视频
14:35Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
Published on: April 17, 2021
8.5K
10:03Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
Published on: January 28, 2020
5.3K
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
420
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
420
01:17Pathophysiology of Heart Failure
1.5K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.5K
01:22Heart Failure Drugs: Diuretics
363
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
363
01:22Heart Failure Drugs: β-Blockers
336
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
336
01:26Heart Failure Drugs: Inotropic Agents
564
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
564
01:29Acute Respiratory Failure-V
132
The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Ensure that patients are monitored continuously for their response to therapy, including changes in...
132